CA Patent

CA3178096A1 — Methods of administering belumosudil for treatment of chronic graft versus host disease

Assigned to Kadmon Corp LLC · Expires 2024-01-14 · 2y expired

What this patent protects

The present disclosure provides methods of administering belumosudil mesylate salt to patients with cGVHD.

USPTO Abstract

The present disclosure provides methods of administering belumosudil mesylate salt to patients with cGVHD.

Drugs covered by this patent

belumosudil-mesylate (BELUMOSUDIL MESYLATE)

Patent Metadata

Patent number: CA3178096A1
Jurisdiction: CA
Classification: —
Expires: 2024-01-14
Drug substance claim: No
Drug product claim: No
Assignee: Kadmon Corp LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.